Literature DB >> 22065720

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

Magali Grange1, Michel Buferne, Grégory Verdeil, Lee Leserman, Anne-Marie Schmitt-Verhulst, Nathalie Auphan-Anezin.   

Abstract

Immunotherapy based on adoptive transfer of tumor antigen-specific CD8(+) T cell (TC) is generally limited by poor in vivo expansion and tumor infiltration. In this study, we report that activated STAT5 transcription factors (STAT5CA) confer high efficiency on CD8(+) effector T cells (eTC) for host colonization after adoptive transfer. Engineered expression of STAT5CA in antigen-experienced TCs with poor replicative potential was also sufficient to convert them into long-lived antigen-responsive eTCs. In transplanted mastocytoma- or melanoma-bearing hosts, STAT5CA greatly enhanced the ability of eTCs to accumulate in tumors, become activated by tumor antigens, and to express the cytolytic factor granzyme B. Taken together, these properties contributed to an increase in tumor regression by STAT5CA-transduced, as compared with untransduced, TCs including when the latter control cells were combined with infusion of interleukin (IL)-2/anti-IL-2 complexes. In tumors arising in the autochthonous TiRP transgenic model of melanoma associated with systemic chronic inflammation, endogenous CD8(+) TCs were nonfunctional. In this setting, adoptive transfer of STAT5CA-transduced TCs produced superior antitumor effects compared with nontransduced TCs. Our findings imply that STAT5CA expression can render TCs resistant to the immunosuppressive environment of melanoma tumors, enhancing their ability to home to tumors and to maintain high granzyme B expression, as well as their capacity to stimulate granzyme B expression in endogenous TCs. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065720     DOI: 10.1158/0008-5472.CAN-11-2187

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Authors:  Lenka V Hurton; Harjeet Singh; Amer M Najjar; Kirsten C Switzer; Tiejuan Mi; Sourindra Maiti; Simon Olivares; Brian Rabinovich; Helen Huls; Marie-Andrée Forget; Vrushali Datar; Partow Kebriaei; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

3.  The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome.

Authors:  Iosifina P Foskolou; Laura Barbieri; Aude Vernet; David Bargiela; Pedro P Cunha; Pedro Velica; Eunyeong Suh; Sandra Pietsch; Rugile Matuleviciute; Helene Rundqvist; Dominick McIntyre; Ken G C Smith; Randall S Johnson
Journal:  Blood Adv       Date:  2020-09-22

4.  Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

Authors:  Marilyn Giordano; Coralie Henin; Julien Maurizio; Claire Imbratta; Pierre Bourdely; Michel Buferne; Lukas Baitsch; Laurent Vanhille; Michael H Sieweke; Daniel E Speiser; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  EMBO J       Date:  2015-07-02       Impact factor: 11.598

Review 5.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

6.  IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.

Authors:  Jinsheng Weng; Kelsey E Moriarty; Flavio Egidio Baio; Fuliang Chu; Sung-Doo Kim; Jin He; Zuliang Jie; Xiaoping Xie; Wencai Ma; Jianfei Qian; Liang Zhang; Jing Yang; Qing Yi; Sattva S Neelapu; Larry W Kwak
Journal:  Oncoimmunology       Date:  2016-10-07       Impact factor: 8.110

7.  Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.

Authors:  Magali Grange; Marilyn Giordano; Amandine Mas; Romain Roncagalli; Guylène Firaguay; Jacques A Nunes; Jacques Ghysdael; Anne-Marie Schmitt-Verhulst; Nathalie Auphan-Anezin
Journal:  Immunology       Date:  2015-06-15       Impact factor: 7.397

8.  CXCR3 expression defines a novel subset of innate CD8+ T cells that enhance immunity against bacterial infection and cancer upon stimulation with IL-15.

Authors:  Steve Oghumu; Cesar A Terrazas; Sanjay Varikuti; Jennifer Kimble; Stephen Vadia; Lianbo Yu; Stephanie Seveau; Abhay R Satoskar
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

Review 9.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

10.  Profound impairment of adaptive immune responses by alkylating chemotherapy.

Authors:  Adam J Litterman; David M Zellmer; Karen L Grinnen; Matthew A Hunt; Arkadiusz Z Dudek; Andres M Salazar; John R Ohlfest
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.